M
Margaret Schot
Researcher at Netherlands Cancer Institute
Publications - 26
Citations - 1779
Margaret Schot is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Pharmacokinetics. The author has an hindex of 15, co-authored 26 publications receiving 1616 citations.
Papers
More filters
Journal ArticleDOI
Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918
C. M. F. Kruijtzer,J. H. Beijnen,Hilde Rosing,W.W. ten Bokkel Huinink,Margaret Schot,R. C. Jewell,Elaine M. Paul,J.H.M. Schellens +7 more
TL;DR: Coadministration of the BCRP and P-gp inhibitor GF120918 resulted in a significant increase of the systemic exposure of oral topotecan.
Journal ArticleDOI
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
M. Donker,Marieke E. Straver,Jelle Wesseling,Claudette E. Loo,Margaret Schot,C.A. Drukker,Harm van Tinteren,Gabe S. Sonke,Emiel J. Th. Rutgers,Marie-Jeanne T. F. D. Vrancken Peeters +9 more
TL;DR: This study shows that marking and selectively removing metastatic lymph nodes after neoadjuvant systemic treatment has a high identification rate and a low false negative rate and the tumor response in the marked lymph node may be used to tailor further axillary treatment after NST.
Journal ArticleDOI
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
Jetske M. Meerum Terwogt,Wim W. ten Bokkel Huinink,Jan H.M. Schellens,Margaret Schot,I.A.M. Mandjes,Maria G Zurlo,Marurizio Rocchetti,Hilde Rosing,Koopman Fj,Jos H. Beijnen +9 more
TL;DR: The presented phase I study with PNU166945, a water-soluble polymeric drug conjugate of pac litaxel, shows an alteration in pharmacokinetic behavior when paclitaxel is administered as a polymer-bound drug, Consequently, the safety profile may differ significantly from standard pac Litaxel.
Journal ArticleDOI
Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel
Mirte M. Malingré,Dick J. Richel,Jos H. Beijnen,Hilde Rosing,Koopman Fj,Wim W. ten Bokkel Huinink,Margaret Schot,Jan H.M. Schellens +7 more
TL;DR: Coadministration of oral CsA strongly enhanced the oral bioavailability of docetaxel and form the basis for the further development of a clinically useful oral formulation of docentaxel.
Journal ArticleDOI
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Jetske M. Meerum Terwogt,Gerard Groenewegen,Dick Pluim,Marc Maliepaard,Matthijs M. Tibben,Albert Huisman,Wim W. ten Bokkel Huinink,Margaret Schot,Helen Welbank,Emile E. Voest,Jos H. Beijnen,Jan H.M. Schellens +11 more
TL;DR: The results of this phase I trial show that the pharmacokinetic behaviour of cisplatin is significantly altered by its encapsulation in Stealth liposomes, resulting in high cholesterol concentrations and relatively low concentrations of (free) platinum in plasma, WBC and tumour tissue, which may explain the observed differences between the toxicity profiles of SPI-77.